Omega-3 shows no benefit for multiple sclerosis, study finds
The supplementation with omega-3 fatty acids has no benefit in treating multiple sclerosis (MS), according to a clinical trial that appeared in the JAMA’s Archives of Neurology. However, researchers acknowledged the randomized controlled trial was underpowered.
The study investigated the effects of omega-3 fatty acid supplementation as a single therapy or in combination with interferon beta-1a, a drug used in the treatment of MS, on the effects of disease activity.
Researchers assessed 92 patients with MS in the double-blind, placebo-controlled trial, using magnetic resonance imaging to measure disease activity by the number of new lesions in the brain.
There was no difference between the 2 groups in the number of relapses or lesions during the first 6 months of treatment or after 24 months, researchers said. In addition, no differences were detected either in fatigue or quality-of-life scores.
Researchers noted that their results were in contrast with 2 other studies reporting a possible positive effect.The authors commented that their data does not suggest omega-3 fatty acid supplementation is harmful, or that such supplementation interfered with interferon beta treatment, which they noted can reduce disease activity in the relapsing-remitting course of MS.
MORE ARTICLES IN THIS ISSUE
"The labels of 2 formulations of finasteride, used to treat enlarged prostate and male-pattern baldness, are being revised to indicate that additional sexual side effects may persist after the drug has been discontinued, FDA announced"
"Phthalate metabolites, chemicals commonly used in plastics, cosmetics, and pharmaceuticals, were linked to an increased risk for the development of type 2 diabetes in the elderly, a recent study found. "
A set of 11 evidence-based recommendations for managing pain with pharmacotherapy in patients suffering inflammatory arthritis were reported by an international panel online March 24 in Rheumatology.
"Doctors debate whether men with elevated cholesterol who are otherwise healthy should still take statins, in a new series in JAMA, Dueling Viewpoints. "